WB, IP, IF-IC, FC-FP, ChIP
H
Endogenous
50, 70
Rabbit IgG
#O75444
4094
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
| Immunofluorescence (Immunocytochemistry) | 1:200 - 1:800 |
| Flow Cytometry (Fixed/Permeabilized) | 1:400 - 1:1600 |
| Chromatin IP | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human c-Maf protein.
Background
Transcription factor c-Maf, also known as MAF and V-maf musculoaponeurotic fibrosarcoma oncogene homolog, is a basic leucine zipper transcription factor (bZIP) in the large Maf protein subclass and belongs to the AP-1 superfamily (1). In humans, there are three c-Maf isoforms and in mice, only two isoforms have been characterized (2). Maf proteins contain a highly conserved ancillary DNA binding domain, N-terminal to the basic domain, and bind to relatively long DNA sequences termed Maf-recognition elements (MAREs) (3). c-Maf can form homodimers and heterodimers with other bZIP proteins like Jun and Fos, as well as non-bZIP proteins (4,5). c-Maf plays an important role in lens fiber cell development, bone development, apoptosis, and the immune system (6,7). In T cells, c-Maf expression is induced by TCR stimulation, and sustained by co-stimulatory signals, and/or cytokines like IL-4, IL-6, TGF-β, and IL-27 (8-12). In macrophages, c-Maf is required for self-renewal and promotes IL-10 production while inhibiting IL-12 (13,14). c-Maf plays a critical role in intestinal immune homeostasis, regulating ILC3s, Th17 cells, γδ T cells, and regulatory T (Treg) cells (7). c-Maf is an oncogene that contributes to the progression of some hematological malignancies and is expressed in other cancers but is not always correlated with poor prognosis (15,16).
- Nishizawa, M. et al. (1989) Proc Natl Acad Sci USA 86, 7711-5.
- Imbratta, C. et al. (2020) Front Immunol 11, 206.
- Kataoka, K. et al. (1994) Mol Cell Biol 14, 700-12.
- Kerppola, T.K. and Curran, T. (1994) Oncogene 9, 675-84.
- Huang, W. et al. (2002) J Biol Chem 277, 50668-75.
- Kawauchi, S. et al. (1999) J Biol Chem 274, 19254-60.
- Cosovanu, C. et al. (2022) J Exp Med 219, e20220233. doi: 10.1084/jem.20220233.
- Bauquet, A.T. et al. (2009) Nat Immunol 10, 167-75.
- Kurata, H. et al. (1999) Immunity 11, 677-88.
- Yang, Y. et al. (2005) J Immunol 174, 2720-9.
- Xu, J. et al. (2009) J Immunol 182, 6226-36.
- Apetoh, L. et al. (2010) Nat Immunol 11, 854-61.
- Soucie, E.L. et al. (2016) Science 351, aad5510.
- Cao, S. et al. (2002) J Immunol 169, 5715-25.
- Morito, N. et al. (2006) Cancer Res 66, 812-9.
- Uhlen, M. et al. (2017) Science 357, eaan2507. doi: 10.1126/science.aan2507.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized) ChIP: Chromatin IP
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
